Global Hospital Acquired Infections Market - 2022-2029

Global Hospital Acquired Infections Market - 2022-2029

Market Overview

Hospital Acquired Infections Market is expected to grow at a high CAGR of 3.8% during the forecasting period (2022-2029).

Hospital-acquired infections, sometimes called healthcare-associated infections, get when the patient receives drug at a healthcare facility or from physicians. The infection can get into the patient's lungs, blood, skin and digestive or urinary tract. Types of healthcare infections include catheter-associated urinary tract infection, surgical site infection, sepsis and others. To treat these types of infections, antiviral or antibacterial drugs are used.

Market Dynamics

The hospital-acquired infections market growth is driven by the rising burden of chronic disease, increasing funding from government and non-government sectors, growing instances of hospital-acquired infection, and research and development activities.

The rising incidence of hospital-acquired infection is expected to drive the market growth

The growing burden of chronic disease led to an increased number of patients visiting the hospital to treat the disease. As per the article published in statPearls 2022, The risk factors for HAI include immunosuppression, length of stay in the hospital, older age, multiple underlying comorbidities, mechanical ventilatory support, frequent visits to healthcare facilities, recent invasive procedures, indwelling devices, and stay in an intensive care unit (ICU). However, hospitalizations play a major role in managing acute illnesses and enhance the risk of susceptible patients for multiple nosocomial and often antimicrobial-resistant pathogens. In the last few years, hospitals have started caring for hospital-acquired infections. Several hospitals have created infection tracking and surveillance systems, along with strong prevention strategies, to minimize the rate of hospital-acquired infections.

In addition, the infections are observed closely by agencies such as the National Healthcare Safety Network (NHSN), the National Institute of Health and Care Excellence (NICE), and the Centre for Disease Control and Prevention (CDC). According to NICE, 300,000 people are diagnosed with HCAI in England only yearly, costing the NHS an estimated £1 billion yearly. In addition, in Europe, hospital-acquired pneumonia affects 0.5% to 1.0% of hospitalized patients and is the most common healthcare-associated infection contributing to death. At least 5% of surgical patients develop a surgical site infection.

The side effects associated with drugs will hamper the growth of the market

However, a hospital that acquires infection drugs has side effects. For instance, antiviral drugs such as ganciclovir, and acyclovir's side effects are cough, dry mouth, diarrhea, dizziness, fatigue, headaches, insomnia, joint pain or muscle pain, nausea or vomiting, and skin rash limits the market growth.

COVID-19 Impact Analysis

The rapid spread of COVID-19 within long-term care facilities is the main cause of the ease of transmission and the need for heightened precautions in all care settings. As per the article published in Healthcare journals in August 2022, The COVID-19 pandemic has massively affected healthcare systems globally, causing a possible reduction in attention to traditional infection prevention programs. Pneumonia (PN) was the most common HAI, followed by urinary tract infections (UTI) and surgical site infections (SST. The Italy survey identified a local HAI prevalence of 9.0%, revealing an increase compared to pre-pandemic values (7.3%).

In addition, to take precautions, the government authorities published guidelines. For instance, the Centers for Disease Control and Prevention, World Health Organization and European Center for Disease Prevention and Control all updated guidelines to mention the importance of dedicated medical equipment or the disinfection of non-critical patient-care devices for patients with known or suspected COVID-19 to prevent from the hospital-acquired infection. In addition, The Society for Healthcare Epidemiology of America and Infectious Disease Society of America also released guidance about using single-patient and individually packaged products to reduce the risk of cross-contamination and the transmission of pathogens such as Methicillin-Resistant Staphylococcus Aureus (MRSA) and Clostridium difficile. Overall, COVID-19 positively impacted the market.

Segment Analysis

The Ventilator-associated Pneumonia (VAP) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Ventilator-associated pneumonia (VAP) segment is expected to boost the market throughout the forecast. Hospital-acquired pneumonia (HAP), Ventilator-associated Pneumonia (VAP), and healthcare-associated pneumonia (HCAP) remain the main causes of morbidity and mortality despite advances in antimicrobial therapy, better supportive care modalities, and the use of a wide range of preventive measures. As per NCBI, the presence of HAP raises hospital stays by an average of 7 to 9 days per patient and has been reported to produce an excess cost of more than $40,000 per patient. Furthermore, HAP accounts for up to 25% of all ICU infections and more than 50% of the antibiotics prescribed. VAP occurs in 9–27% of all intubated patients. In ICU patients, around 90% of episodes of HAP occur during mechanical ventilation. In mechanically ventilated patients, the incidence increases with the duration of ventilation. The risk of VAP is highest early in the hospital stay and is estimated to be 3%/day during the first 5 days of ventilation, 2%/day during Days 5 to 10 of ventilation, and 1%/day after this. Because most mechanical ventilation is short-term, approximately half of all episodes of VAP occur within the first 4 days of mechanical ventilation. Resulting in increasing demand for the Drug of HAP. The antibiotics used for HAP Drug include Cefepime, Ceftazidime, Carbapenems, Aminoglycosides, and Gentamicin.

Geographical Analysis

North America region holds the largest market share of the global hospital acquired infections market

North America dominates the hospital-acquired infections market and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the growing population with chronic disease, increasing old population and rising healthcare expenditure. The Centers for Disease Control (CDC) anticipates that in American hospitals alone, HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. Of these infections: 32 % of all healthcare-acquired infections are urinary tract infections, 22 % are surgical site infections, 15 % are pneumonia (lung infections), and 14 % are bloodstream infections.

In addition, in August 2022, the Public Health Agency of Canada estimated that approximately 2% of patients admitted to large academic Canadian hospitals will have acquired an infection during their hospital stay and that at any time, 3%–10% of hospitalized patients are either infected with or a carrier of antimicrobial-resistant organisms. The rising incidence of hospital-acquired infection leads to increasing demand for drug in the North American region.

Competitive Landscape

The hospital acquired infections market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are 3M, Advanced Sterilization Products, Becton Dickinson and company, STERIS Corp., F. Hoffmann-La Roche Ltd, Cantel Medical Corp., Belimed AG, Abbott Laboratories, Pfizer Inc., and Bayer AG among others. The major players are adopting several growth strategies such as Drug Type launches, acquisitions, and collaborations, which are contributing to the growth of the hospital acquired infections market globally.

For instance,

• In June 2021, STERIS plc acquired the Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers.

3M

Overview:

3M is an American company founded in 1902 and headquartered in the United States. The company provides the solution to identify and reduce infection and transmission risks and provide science-based solutions that can help you protect patients, staff and everyone who enters the hospital. The solutions include hand hygiene, wound care and others.

Drug Type Portfolio:

Purell TFX Gel Refill: It kills 99.9% of germs on contact; this wall dispenser refill can be used in hospitals by both patients’ family members and healthcare personnel. It is available in smaller bottles and can be kept at a nurses’ station or in the user's pocket.

The global hospital acquired infections market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.